Helicobacter pylori: what ulcer follow-up records revealed
Helicobacter pylori entered the peptic ulcer research record through observations of bacteria and inflammation, but later investigations followed something harder to capture in a biopsy: whether a healed ulcer returned. A London study published in 1994 separated initial bacterial clearance from lasting eradication. A Hong Kong trial published in 2000 compared recurrence after surgery. Their measurements linked infection with the course of ulcer disease across time. The National Institute of Diabetes and Digestive and Kidney Diseases now identifies Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs, or NSAIDs, as the two most common causes of peptic ulcers, sores in the stomach or duodenal lining.
R. P. Logan and colleagues at the Central Middlesex Hospital investigated 45 patients with duodenal ulcers in the 1994 study. Their evidence included tissue examination, bacterial culture and breath measurements. Forty-four patients were available for follow-up after an antibacterial intervention. Immediately afterward, breath-test results indicated bacterial clearance in every one of them. At the second endoscopic examination, a median of 20 days after the intervention began, 33 of the 44 ulcers had healed. Ten of the remaining eleven were smaller and subsequently healed without additional treatment.
Lasting bacterial eradication was recorded in 28 of those 44 patients, with a median follow-up of 10.2 months. Two ulcers that had initially healed returned three weeks later; both patients had bacteria resistant to one of the antibiotics studied. The immediate appearance of clearance therefore exceeded the proportion with sustained eradication. This was an open study, without a randomly assigned comparison group. Its results documented healing alongside changes in bacterial status, while its design limited how confidently those changes could be attributed to the intervention alone.
Enders Ng and colleagues examined a different clinical setting in their 2000 publication: patients whose duodenal ulcers had perforated and undergone surgical repair. Among 129 patients assessed, 104 had Helicobacter pylori infection. Ninety-nine infected patients entered the randomized comparison. Both groups had received repair of the perforation; one was assigned an intervention directed at the bacterium, while the comparison group received acid suppression alone. Early ulcer healing was similar between groups, at 82% and 87%. The contrast emerged during subsequent follow-up: the reported one-year relapse rates were 4.8% and 38.1%, respectively.
Those percentages came from a selected surgical population in Hong Kong, rather than a survey of everyone with stomach pain. Nine randomized patients missed the first follow-up endoscopy. At the one-year stage, 18 recurrences were documented, and 15 were associated with persistent infection. Some patients in the comparison group had also received additional antibiotics for postoperative illnesses, complicating the intended separation between groups. The investigators disclosed those events in the trial results. Their observations connected bacterial persistence with recurrent ulceration after the original hole had been repaired, extending the evidence beyond uncomplicated ulcers.
A laboratory investigation published by Eitaro Aihara and colleagues in PLOS Pathogens in 2014 examined the interaction at a much smaller scale. In mice with experimentally injured stomach tissue, Helicobacter pylori accumulated preferentially at damaged areas and delayed repair. Fluorescent imaging captured accumulation at microscopic injury sites within five minutes. The researchers compared ordinary bacteria with variants impaired in movement or in sensing chemical gradients. Bacteria unable to move failed to colonize the tissue, whereas bacteria impaired in chemical sensing could colonize without the same preference for the injured region. These were observations in an animal model, with injuries created for the experiment, rather than measurements of how an individual human ulcer first developed.
The chemical-sensing variant still modestly delayed healing. Movement toward damage and interference with repair were consequently related but separable findings. The experiment supplied a possible biological connection between bacterial location and persistent injury; it did not replace the human follow-up evidence. Its comparisons also included resident Lactobacillus bacteria, which did not show the same preference for ulcerated tissue. The location of bacteria within an injured stomach was itself a measurable feature of the disease process.
The NSAID evidence establishes a separate boundary around the bacterial explanation. In 2023, Mart van de Laar and colleagues reanalyzed data from two naproxen trials, examining 426 participants from their naproxen treatment groups. The original eligibility criteria required a negative Helicobacter pylori stool-antigen result. About one-third of participants who developed an endoscopically detected ulcer reported no gastrointestinal pain symptoms. Symptom distributions were similar among participants with and without ulcers. Funded by Grünenthal, the analysis used existing trial data and disclosed the company's role. It documented ulcer injury in a population selected without detected infection, alongside the distinct research linking bacterial persistence to recurrence. Infection was a major established cause, while the clinical records retained evidence of another route to the same anatomical injury.
- National Institute of Diabetes and Digestive and Kidney Diseases, Definition & Facts for Peptic Ulcers, reviewed 2022 — www.niddk.nih.gov
- Logan and colleagues, One week’s anti-Helicobacter pylori treatment for duodenal ulcer, Gut, 1994 — pmc.ncbi.nlm.nih.gov
- Ng and colleagues, Eradication of Helicobacter pylori Prevents Recurrence of Ulcer After Simple Closure of Duodenal Ulcer Perforation, Annals of Surgery, 2000 — pmc.ncbi.nlm.nih.gov
- Aihara and colleagues, Motility and Chemotaxis Mediate the Preferential Colonization of Gastric Injury Sites by Helicobacter pylori, PLOS Pathogens, 2014 — journals.plos.org
- van de Laar and colleagues, Gastrointestinal symptoms and NSAID-associated ulcers: pooled naproxen trial data, PLOS ONE, 2023 — journals.plos.org